Clinical Trials Directory

Trials / Completed

CompletedNCT05102474

Dermatologic Research Evaluation and Monitoring of Sleep in Moderate-to-Severe Psoriasis

Status
Completed
Phase
Study type
Observational
Enrollment
24 (actual)
Sponsor
University of California, San Francisco · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

Getting enough sleep is important for maximizing health and well-being. When it comes to health, sleep is as vital as regular exercise and eating a balanced diet. Not getting enough sleep can lead to health problems like heart attacks, diabetes, and even cancer. Since individuals with psoriasis have these same health problems, getting better sleep may help to keep them happier and healthier. This study will look at how individuals with psoriasis sleep and if their sleep is different than indivuduals without psoriasis.

Detailed description

A growing body of literature has revealed that individuals with psoriasis are more likely to report sleep disturbance when compared to the general population. The cross-sectional study presented here will allow the investigators to objectively and rigorously measure sleep architecture in psoriasis patients and compare it to healthy controls, If sleep dysfunction is confirmed in this population, then clinical interventions such as screening for sleep disturbance or promoting sleep hygiene could lead to meaningful improvements in patients' health, longevity, and overall quality of life.

Conditions

Interventions

TypeNameDescription
OTHERPolysomnography (PSG)PSG is the gold standard for objectively measuring sleep in the laboratory setting. The procedure consists of electrodes measuring brain activity (electroencephalography, EEG), eye movements (electrooculography, EOG), muscle activity (electromyography, EMG), respiratory events, snoring activity, blood oxygen saturation, and body position. Video surveillance during the sleep study can also monitor for itching events that occur during the night.

Timeline

Start date
2022-02-15
Primary completion
2024-07-03
Completion
2024-07-03
First posted
2021-11-01
Last updated
2025-08-06

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05102474. Inclusion in this directory is not an endorsement.